Advertisement
Screener

VISTAGEN THERAPEUTICS, INC. (VTGN) Gains (Losses) on Recourse Debt

2.8 / 5 stars · 68/120 Roast Me

VISTAGEN THERAPEUTICS, INC. Gains (Losses) on Recourse Debt

VISTAGEN THERAPEUTICS, INC. (VTGN) reported Gains (Losses) on Recourse Debt of $2.37 million for the 9-month period ending 2014-12-31, per its 10-Q filed 2015-02-17.

Discontinued › Income Statement › Other Income

us-gaap:GainsLossesOnRecourseDebt · last filed 2015-02-17

  • VISTAGEN THERAPEUTICS, INC. gains (losses) on recourse debt for the quarter ending 2014-12-31 was $0.00.
Period endGains (Losses) on Recourse Debt 3 monthGains (Losses) on Recourse Debt 6 monthGains (Losses) on Recourse Debt 9 month
2014-12-31$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-02-17
$2.37M
10-Q · filed 2015-02-17
2014-09-30$2.37M
10-Q · filed 2014-11-19

Similar stocks

Stock NameCountryMarket CapPE Ratio
MUSTANG BIO, INC. (MBIO)United States$0.013B
AEON Biopharma, Inc. (AEON)United States$0.013B-0.36
LISATA THERAPEUTICS, INC. (LSTA)United States$0.014B-2.13
Tempest Therapeutics, Inc. (TPST)United States$0.013B
Aspire Biopharma Holdings, Inc. (ASBP)United States$0.012B-0.60
BIOVIE INC. (BIVI)United States$0.012B
BullFrog AI Holdings, Inc. (BFRG)United States$0.014B
ADIAL PHARMACEUTICALS, INC. (ADIL)United States$0.012B
Vyome Holdings, Inc (HIND)United States$0.014B-1.38
Tvardi Therapeutics, Inc. (TVRD)United States$0.014B